Allan van Konynenburg discussed trends in the supply chain such as artificial intelligence, blockchain, and cell and gene therapies at CTS Europe. Image credit: Jenna Philpott/GlobalData.

Last year, eight cell and gene therapies were approved in the US and EU, with the scope only continuing to increase. With this growth, experts gathered at Clinical Trial Supply (CTS) Europe to discuss the challenges these blockbuster treatments pose to the supply chain. 

Leading the session “Current challenges in the supply chain and future trends”, global depot network director at the CRO SanaClis Allan van Konynenburg delved into trends such as artificial intelligence, blockchain, and cybersecurity, but “out of all trends, cell therapy is front and centre in terms of what’s possible,” he said. 

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s Pharma Intelligence Centre, the cell and gene therapy market is projected to reach sales of $80bn by 2029 and is expected to grow at a compound annual growth rate (CAGR) of 25%–30% over the next few years. However, despite the potential, they present challenges for the supply chain. 

One of the challenges is time and temperature sensitivity. The therapies often have short half-lives, needing ultra-cold ice/liquid nitrogen storage that requires seamless cold-chain capabilities and contingency workflows: “How do we how do we ensure that we have that robust seamless supply chain in place and have the right sort of capabilities?” said Konynenburg on handling this. 

Another challenge is the financial burden to companies – cell and gene therapies have high-value pricing due to their complexity, meaning robust mitigation is needed for risks involved in the supply chain.  

See Also:

On pricing, Konynenburg said: “If we think of traditional commercialisation models, including pricing and contracting models – one size doesn’t fit all. We expect to see an exponential increase in the number of gene therapies, with an industry ready to rethink some of those commercial commercialisation models around pricing and contract.”  

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Concluding the session, Konynenburg looked ahead to the rest of 2024, saying geopolitical tensions and upcoming elections that can have an impact on the industry mean “that we continue to live in uncertain times”. 

Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva. Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.